🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the fight against superbug strains of the bacteria, according to researchers.

A Global Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting over 82 million infections per year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This medication, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the management of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Global Access

Based on results published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which involves a dual-drug approach. The study included over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Doctors treating patients have expressed hope. Having a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.